Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan;45(1):e61-e62.
doi: 10.1097/RLU.0000000000002668.

18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence

Fahad Marafi  1 , Arun Sasikumar  2 , Wael Fathallah  3 , Abdulredh Esmail  1
Affiliations
Case Reports

18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence

Fahad Marafi et al. Clin Nucl Med. 2020 Jan.

Abstract

A 64-year-old man with a known case of right parietal lobe glioblastoma multiforme operated on in August 2018 was referred for F-FDG PET/CT with a clinical suspicion of recurrence. He underwent F-FDG and F-PSMA 1007 scans. Both the scans showed intense tracer uptake in right parietal lobe lesion, which concurred with MRI findings of recurrent disease and was later proven on histopathologic examination as recurrence. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of suspected glioblastoma recurrence. Considering its similarity to PSMA-617, it may be used as a surrogate imaging tracer for potential theranostic application using alpha or beta emitters.

PubMed Disclaimer

References

    1. Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med. 2017;42:e41–e48.
    1. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med. 2018;43:e304–e309.
    1. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–495.
    1. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45:340–347.
    1. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688.

Publication types